vascuCAP vs iPredict Eye Screening
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (vascuCAP) specializes in direct cardiovascular risk assessment through AI-enabled CT angiography analysis and detailed plaque quantification. In contrast, Tool B (iPredict Eye Screening) primarily offers AI-powered screening for ophthalmic conditions like AMD, DR, and Glaucoma, with an added capability for systemic disease risk prediction derived from retinal imaging. While both tools provide insights into stroke and heart attack risk, they do so via distinct diagnostic modalities and cater to different primary clinical workflows.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is an AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk. iPredict Eye Screening is an AI-powered screening tool that uses retinal imaging for the early detection of age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma, and also provides risk prediction for systemic diseases like stroke and heart attack.
vascuCAP provides histologically-validated quantification of plaque components, such as lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage, from CT angiograms to stratify risk for stroke and heart attack and support personalized treatment decisions. iPredict Eye Screening offers an online health risk prediction system for diabetic, stroke, and heart attack patients, based on retinal analysis.
vascuCAP offers DICOM integration and PACS/EMR interoperability for seamless workflow. iPredict Eye Screening integrates with Electronic Health Record (EHR) solutions and provides AI-based telemedicine services.
vascuCAP is designed for Cardiology, Radiology, and Vascular Surgery, focusing on patients requiring cardiovascular risk assessment via CT angiography. iPredict Eye Screening targets Family Medicine, Internal Medicine, and Ophthalmology, screening patients aged 50 years and older for AMD, DR, and Glaucoma.
vascuCAP's plaque quantification is histologically-validated. iPredict Eye Screening reports high accuracy, with approximately 95% on average, and specifically for AMD, it has a sensitivity of 86.86% and a specificity of 94.13%.